Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
The latest drug development news and highlights from our US FDA Performance Tracker.
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.